Levis MJ - Search Results

1

A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia.

Gojo I, Beumer JH, Pratz KW, McDevitt MA, Baer MR, Blackford AL, Smith BD, Gore SD, Carraway HE, Showel MM, Levis MJ, Dezern AE, Gladstone DE, Ji JJ, Wang L, Kinders RJ, Pouquet M, Ali-Walbi I, Rudek MA, Poh W, Herman JG, Karnitz LM, Kaufmann SH, Chen A, Karp JE. Gojo I, et al. Among authors: levis mj. Clin Cancer Res. 2017 Feb 1;23(3):697-706. doi: 10.1158/1078-0432.CCR-16-0984. Epub 2016 Aug 8. Clin Cancer Res. 2017. PMID: 27503200 Free PMC article. Clinical Trial.

2

A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations.

Levis M, Tse KF, Smith BD, Garrett E, Small D. Levis M, et al. Blood. 2001 Aug 1;98(3):885-7. doi: 10.1182/blood.v98.3.885. Blood. 2001. PMID: 11468194 Free article.

3

A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo.

Levis M, Allebach J, Tse KF, Zheng R, Baldwin BR, Smith BD, Jones-Bolin S, Ruggeri B, Dionne C, Small D. Levis M, et al. Blood. 2002 Jun 1;99(11):3885-91. doi: 10.1182/blood.v99.11.3885. Blood. 2002. PMID: 12010785 Free article.

4

Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor.

Tse KF, Allebach J, Levis M, Smith BD, Bohmer FD, Small D. Tse KF, et al. Leukemia. 2002 Oct;16(10):2027-36. doi: 10.1038/sj.leu.2402674. Leukemia. 2002. PMID: 12357354

5

Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay.

Murphy KM, Levis M, Hafez MJ, Geiger T, Cooper LC, Smith BD, Small D, Berg KD. Murphy KM, et al. Among authors: levis m. J Mol Diagn. 2003 May;5(2):96-102. doi: 10.1016/S1525-1578(10)60458-8. J Mol Diagn. 2003. PMID: 12707374 Free PMC article.

6

Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia.

Smith BD, Levis M, Beran M, Giles F, Kantarjian H, Berg K, Murphy KM, Dauses T, Allebach J, Small D. Smith BD, et al. Blood. 2004 May 15;103(10):3669-76. doi: 10.1182/blood-2003-11-3775. Epub 2004 Jan 15. Blood. 2004. PMID: 14726387 Free article. Clinical Trial.

7

In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects.

Levis M, Pham R, Smith BD, Small D. Levis M, et al. Blood. 2004 Aug 15;104(4):1145-50. doi: 10.1182/blood-2004-01-0388. Epub 2004 May 4. Blood. 2004. PMID: 15126317 Free article.

8

Recent advances in the development of small-molecule inhibitors for the treatment of acute myeloid leukemia.

Levis M. Levis M. Curr Opin Hematol. 2005 Jan;12(1):55-61. doi: 10.1097/01.moh.0000148761.23036.e6. Curr Opin Hematol. 2005. PMID: 15604892 Review.

9

Inhibitory anti-FLT3 antibodies are capable of mediating antibody-dependent cell-mediated cytotoxicity and reducing engraftment of acute myelogenous leukemia blasts in nonobese diabetic/severe combined immunodeficient mice.

Piloto O, Levis M, Huso D, Li Y, Li H, Wang MN, Bassi R, Balderes P, Ludwig DL, Witte L, Zhu Z, Hicklin DJ, Small D. Piloto O, et al. Cancer Res. 2005 Feb 15;65(4):1514-22. doi: 10.1158/0008-5472.CAN-04-3081. Cancer Res. 2005. PMID: 15735040

10

Internal tandem duplications of the FLT3 gene are present in leukemia stem cells.

Levis M, Murphy KM, Pham R, Kim KT, Stine A, Li L, McNiece I, Smith BD, Small D. Levis M, et al. Blood. 2005 Jul 15;106(2):673-80. doi: 10.1182/blood-2004-05-1902. Epub 2005 Mar 29. Blood. 2005. PMID: 15797998 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

221 results

Search Page